EUVIMEDEUVIMED entdecken
Open Access

Characteristics Associated With Refractory Course, Blindness, and Treatment Strategy–Related Outcomes in Patients With Mucous Membrane Pemphigoid

Khalaf Kridin, Nina van Beek, Elena Bühler, Anne S Kochan, Mahdy Ranjbar, Stefan Beissert, Detlef Zillikens, Claudia Günther, Enno Schmidt

JAMA Dermatology · 2023

DOI: 10.1001/jamadermatol.2022.5829 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Dermatology, 2023. Verfasst von Khalaf Kridin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck, Lübeck, Germany. Hauptthemen laut MEDLINE: Autoimmune Diseases, Pemphigoid, Benign Mucous Membrane, Pemphigoid, Bullous. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Mucous membrane pemphigoid (MMP) is a rare and heterogeneous subepithelial autoimmune bullous disease with predominant mucosal involvement. Characteristics associated with the disease course and complications are yet to be delineated.

Objectives

To evaluate characteristics associated with refractory disease course and blindness among patients with MMP and to estimate the association of different treatment strategies with the prognostic outcome. Design, Setting, and Participants A retrospective cohort study of consecutive patients diagnosed with MMP and followed up for more than 1 year from 2007 to 2020 in 2 tertiary referral centers. Data were analyzed from January 1, 2009, to June 30, 2020. Main Outcomes and Measures Characteristics associated with refractory disease course and blindness were evaluated using multivariable logistic regression model.

Results

The study encompassed 121 patients with MMP (mean [SD] age, 66.0 [14.0] years; 78 (64.5%) were women), of whom 56 (46.3%) followed a refractory course and 13 (10.7%) developed blindness. Anti–LAD-1 IgA (odds ratio [OR], 3.42; 95% CI, 1.11-10.52; P = .03) and anti–dermal-epidermal/epithelial junction (DEJ) IgG (by indirect immunofluorescence on human salt-split skin; OR, 2.92; 95% CI, 1.26-6.78; P = .01) were significantly associated with refractory course. Development of blindness was associated with older age (≥68 years; OR, 6.38; 95% CI, 1.35-30.16; P = .009), initial presentation with bilateral ocular involvement (OR, 7.92; 95% CI, 2.04-30.68; P = .001), and scarring ocular lesions (OR, 5.11; 95% CI, 1.47-17.79; P = .006). However, 4 (30.8%) and 2 (15.4%) of those experiencing blindness had no ocular scarring lesions and unilateral ocular involvement at the onset of their disease, respectively. Patients progressing to blindness were more likely to be treated by 3 or more immunosuppressive/immunomodulatory drugs (OR, 4.07; 95% CI, 1.17-14.14; P = .02) and by cyclophosphamide (OR, 7.64; 95% CI, 2.24-26.09; P < .001). Patients developing blindness and refractory course were more frequently managed by intravenous immunoglobulin (OR, 7.64; 95% CI, 2.24-26.09; P < .001 and OR, 3.47; 95% CI, 1.42-8.45; P = .005, respectively). Conclusions and Relevance Findings of this cohort study support that patients with MMP with anti–LAD-1 IgA and anti-DEJ IgG reactivity should be carefully monitored. While initial bilateral ocular disease and scarring ocular lesions were associated with blindness, patients initially presenting with unilateral and nonscarring ocular disease may still develop severe vision impairment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autoimmune DiseasesPemphigoid, Benign Mucous MembranePemphigoid, BullousAgedFemaleHumansMaleAutoantibodiesBlindnessCicatrixCohort StudiesImmunoglobulin AImmunoglobulin GMucous MembraneRetrospective StudiesMiddle AgedAged, 80 and over

Substanzen

AutoantibodiesImmunoglobulin AImmunoglobulin G

Autor:innen und Institutionen

  • Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck, Lübeck, Germany.
  • Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
  • Unit of Dermatology and Skin Research Laboratory, Baruch Padeh Medical Center, Poriya, Israel.
  • Department of Dermatology, University of Lübeck, Lübeck, Germany.
  • Department of Dermatology, Carl Gustav Carus University Hospital, TU Dresden, Dresden, Germany.
  • Department of Ophthalmology, University of Lübeck, Lübeck, Germany.

Zitieren

APA

Kridin, K., van Beek, N., Bühler, E., Kochan, A. S., Ranjbar, M., Beissert, S., Zillikens, D., Günther, C., & Schmidt, E. (2023). Characteristics Associated With Refractory Course, Blindness, and Treatment Strategy–Related Outcomes in Patients With Mucous Membrane Pemphigoid. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2022.5829

Vancouver

Kridin K, van Beek N, Bühler E, Kochan AS, Ranjbar M, Beissert S, et al. Characteristics Associated With Refractory Course, Blindness, and Treatment Strategy–Related Outcomes in Patients With Mucous Membrane Pemphigoid. JAMA Dermatology. 2023. doi:10.1001/jamadermatol.2022.5829

BibTeX
@article{Kridin2023,
  author = {Kridin, Khalaf and van Beek, Nina and Bühler, Elena and Kochan, Anne S and Ranjbar, Mahdy and Beissert, Stefan and Zillikens, Detlef and Günther, Claudia and Schmidt, Enno},
  title = {Characteristics Associated With Refractory Course, Blindness, and Treatment Strategy–Related Outcomes in Patients With Mucous Membrane Pemphigoid},
  journal = {JAMA Dermatology},
  year = {2023},
  doi = {10.1001/jamadermatol.2022.5829}
}
Kostenlos starten →